Business Wire

VA-HILTON

27.1.2020 15:35:09 CET | Business Wire | Press release

Share
Hilton Delivers Record-Breaking Growth and Positive Impact in 100th Year of Hospitality

Hilton (NYSE: HLT) announced that its centennial year featured record-breaking growth, awards for its inclusive workplace culture, and continued recognition of positive community impact.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200127005397/en/

“Throughout the last 100 years, Hilton has had a tremendous positive impact on billions of lives across the globe,” said Christopher J. Nassetta, president & chief executive officer, Hilton. “As we look toward the future, we will continue to prioritize sustainable and inclusive growth, enabling us to further strengthen the collective impact we have on the people and communities we serve.”

In 2019, Hilton achieved 6.6 percent net unit growth by adding nearly 470 hotels and reaching 6,110 properties globally with more than 971,000 rooms in 119 countries and territories. The company also grew its development pipeline to more than 387,000 rooms across 15 of its brands, supported by more than 116,000 rooms approved in 72 countries and territories. In addition, Hilton achieved a new construction start record of nearly 87,000 rooms.

“Hilton’s growth and performance are a testament to our resilient business model,” said Kevin Jacobs, chief financial officer, Hilton. “In addition to our record-breaking growth across approvals, construction starts and net units, we are delivering on our commitment to serve any guest, anywhere in the world, for any travel need.”

Record Growth: Effect on Economies

Travel with Purpose: Effect on Communities

  • Launched The Hilton Effect Foundation , dedicated to creating a better world to travel
  • Named the global industry leader in sustainability on the Dow Jones Sustainability Indices (DJSI), the most prestigious ranking for corporate responsibility
  • Recognized as the only hospitality company on Fortune’s Change the World list for the second year in a row
  • Named to climate change “A-List” by the environmental impact nonprofit CDP
  • Expanded decade-long soap recycling program , already the largest in the hospitality industry, to more than 5,300 properties in 70 countries and territories
  • Exceeded Open Doors pledge to connect, prepare or employ one million young people by 2019
  • Invested in local communities by contributing nearly 550,000 volunteering hours at nearly 10,500 events and expanding food donation initiative to all Hilton managed hotels in the U.S. and Canada

Customer Innovations: Effect on Guests

  • Welcomed 178 million guests at its properties worldwide and the 100 millionth Hilton Honors member , growing the award-winning loyalty program by 21 percent to more than 103 million members at year-end
  • Launched a first-of-its-kind travel and hospitality partnership with Lyft , allowing Hilton Honors members to earn and redeem Hilton Honors Points when they ride with Lyft
  • Achieved record numbers of package redemptions through the Hilton Honors Experiences Platform , and hosted intimate music events via an expanded partnership with Live Nation , the world’s leading live entertainment company
  • Partnered with iHeartRadio to allow guests to stream live radio stations, thousands of music playlists and podcasts directly from their TVs through Hilton’s high-tech Connected Room guest technology platform
  • Became the first hospitality company to participate in research aboard the International Space Station , when the DoubleTree chocolate chip cookie became the first food baked in space inside a prototype oven as part of a landmark microgravity experiment

World’s Best Workplace: Effect on Team Members

  • Named #1 Best Company to Work for in the U.S. by Fortune magazine and Great Place to Work®
  • Ranked #2 World’s Best Workplace , appearing on Fortune magazine and Great Place to Work’s® annual list of the 25 World’s Best Workplaces for the fourth consecutive year
  • Recognized by Great Place to Work® in 17 countries and 3 regions including: Argentina #1, Italy #1, Peru #1, Saudi Arabia #1, Turkey #1, United States #1, China #2, Asia #3, United Arab Emirates #3, United Kingdom #3, Australia #3, Mexico #4, Colombia #4, Netherlands #7, Europe #10, Latin America #11, Germany #12, Brazil #14, India #16, Canada #29
  • Named #1 workplace in the U.S. for Parents and Women ; #2 workplace for Millennials by Great Place to Work® and Fortune magazine
  • Named #4 Top 50 Company for Diversity by DiversityInc and received a perfect score on the Human Rights Campaign Corporate Equality Index for the seventh consecutive year
  • Celebrated 100th anniversary with more than 420,000 Team Members** and created more than 25,000 new jobs worldwide***
  • Achieved Operation: Opportunity five-year target of hiring 30,000 veterans, military spouses and caregivers, and expanded military-friendly commitment by pledging to make 25,000 additional hires by 2025, while also enhancing training and development opportunities
  • Expanded family-friendly benefits including an extension to parental leave and an industry-first partnership with Milk Stork to enable Team Members to easily ship or carry breast milk home to their babies while traveling for work

To learn more about Hilton, please visit newsroom.hilton.com .

*Industry data from STR
** Corporate, owned, managed and franchised employees globally
***As a result of opening properties across Hilton’s portfolio

About Hilton

Hilton (NYSE: HLT) is a leading global hospitality company with a portfolio of 18 world-class brands comprising more than 6,100 properties with more than 971,000 rooms, in 119 countries and territories. Dedicated to fulfilling its mission to be the world’s most hospitable company, Hilton welcomed more than 3 billion guests in its 100-year history, earned a top spot on the 2019 World’s Best Workplaces list, and was named the 2019 Global Industry Leader on the Dow Jones Sustainability Indices. Through the award-winning guest loyalty program Hilton Honors, more than 103 million members who book directly with Hilton can earn Points for hotel stays and experiences money can’t buy, plus enjoy instant benefits, including digital check-in with room selection, Digital Key, and Connected Room. Visit newsroom.hilton.com for more information, and connect with Hilton on Facebook , Twitter , LinkedIn , Instagram and YouTube .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye